All In Biotech

NDA 210134 · Amphastar Pharms INC

Baqsimi

Glucagon · Nasal · Antihypoglycemic Agent; Gastrointestinal Motility Inhibitor

Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jul 24, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,154

249 Phase 3, 171 recruiting

FAERS reports

4,232

3,276 serious, 676 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 19, 2026.

BAQSIMI™ is indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes. BAQSIMI ® is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes. ( 1 )

Mechanism: Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.

Therapeutic areas: Gastroenterology and liver

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 17, 2025 Supplement 4 · Efficacy · priority review LabelLetter
  • Jul 24, 2019 Original approval · Type 3 - New Dosage Form LabelLetterReview
1 products under this application
  • BAQSIMI · GLUCAGON 3MG · POWDER, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Glucagon" as an intervention, any sponsor and status, largest first.

All 1,154 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective389
  • dyspnoea375
  • acute kidney injury324
  • hypotension300
  • hypoglycaemia271
  • condition aggravated258
  • toxicity to various agents238
  • nausea237
  • anxiety226
  • haemoptysis224
  • vomiting222
  • death213

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200524
200620
200726
200823
200949
201034
201153
201253
201354
201483
2015230
2016202
2017210
2018207
2019323
2020448
2021436
2022316
2023398
2024369
2025392
2026263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Baqsimi (Glucagon)

2024 spending

$21.5M

Beneficiaries

31,463

43,157 claims

Per beneficiary

$683

$282.93 per unit

View as table
YearSpending
2020$9,007,678
2021$14,337,898
2022$19,127,819
2023$25,476,037
2024$21,504,807

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,332 on PubMed

Sponsor: Amphastar Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.